• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Earnings round-up: Biogen, Lilly & Novartis post Street-beating Q3 results

October 24, 2017 By Sarah Faulkner

Prescription drugsWhen Johnson & Johnson posted its third quarter financial results last week, the healthcare giant credited its revenue growth to the strength of its pharmaceutical business.

Three more pharmaceutical companies posted their Q3 results today, topping revenue and earnings estimates from analysts. Here’s a round-up of Q3 earnings from Biogen (NSDQ:BIIB), Eli Lilly (NYSE:LLY) and Novartis (NYSE:NVS).

Biogen
This Cambridge, Mass.-based biotech posted adjusted earnings of $6.31 per share, beating analysts’ estimates of $5.07 apiece. The company topped revenue expectations, reeling in $3.08 billion.

Sales of Biogen’s spinal muscular atrophy drug, Spinraza, were up 34% compared to last quarter, the company reported, but U.S. sales remained nearly flat quarter-over-quarter – $195 million in sales last quarter compared to $198 million in Q3.

BIIB shares were trading at $309.50 apiece in early-morning activity today, down -6.1%.

Eli Lilly
Driven largely by growth in its diabetes and pharma businesses, Eli Lilly today reported Q3 sales of $5.66 billion, compared to estimates from analysts who were expecting the company to post $5.51 billion in revenue.

The company also posted adjusted earnings of $1.05 per share, beating estimates by 2¢.

After a quarter that beat estimates on Wall Street, the Indiana-based insulin-maker raised its full-year adjusted profit forecast to $4.15 – $4.25 per share and upped its revenue forecast to $22.4 billion – $22.7 billion

Lilly added that it is considering a potential sale or an initial public offering for its Elanco animal health business, due to increased competition in the area.

LLY shares were trading at $85.06 apiece in early-morning activity today, down -2.4%.

Novartis
Novartis posted sales of $12.41 billion on earnings of $1.29 per share today, topping estimates on Wall Street where analysts were expecting sales of $12.17 billion on earnings of $1.25 per share.

The company landed a major victory this quarter after its CAR-T cell therapy, known as Kymriah, was approved as the first of its kind in the U.S.

Novartis also said today that it plans to delay its decision on whether or not to sell its Alcon eye care unit, saying that its “growth acceleration plan is beginning to generate growth, executed by a strong management team.”

The company is slated to make a final decision about the future of the business in 2019.

NVS shares were trading at $83.32 apiece in early-morning activity today, down -3%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Biogen Idec, Eli Lilly & Co., Novartis

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS